Volition Debuts Innovative Nu.Q® Vet Cancer Test at Upcoming WVC Conference in Las Vegas

Introduction

VolitionRx Limited, known for its groundbreaking work in epigenetics, is set to make a significant mark at the upcoming 97th Annual Western Veterinary Conference (WVC) in Las Vegas, from March 2 to 5, 2025. With an expectation of over 20,000 veterinary professionals in attendance, Volition's participation emphasizes its commitment to enhancing veterinary diagnostics, particularly through the use of its innovative Nu.Q® Vet Cancer Test.

Event Details

Taking place at the Mandalay Bay Convention Center, this year's WVC promises to be a focal point for veterinary advancements and discussions. Volition will have a dedicated presence at exhibition booth #2943, where attendees can engage with its team and learn more about the Nu.Q® Vet Cancer Test. This test stands out as a user-friendly, cost-effective solution that delivers rapid results for the detection of seven common cancers in dogs.

Featured Presentations

Volition's commitment to education and community engagement is evident through the lineup of presentations scheduled during the conference:
1. Monday, March 3, 2025 - Dr. Sue Ettinger, affectionately dubbed 'Dr. Sue Cancer Vet', will discuss the journey of canine cancer detection and treatment. This presentation will take place in Ballroom F, Level 2, from 2:00 PM to 2:50 PM.
2. Tuesday, March 4, 2025 - Dr. Brett Cordes will explore the practical application of the Nu.Q® Vet Cancer Test, offering veterinary professionals insights into its usage in treatment settings. This session will occur at the Western Frontier, Learning Hub, Exhibit Hall Level 1, from 10:30 AM to 11:00 AM.
3. Wednesday, March 5, 2025 - Dr. Tom Butera, the CEO of Volition Veterinary Diagnostics Development LLC, will present on early cancer detection through the Nu.Q® Vet Cancer Test, highlighting the importance of proactive monitoring. This concludes the series of presentations in Ballroom J, Level 2, from 12:10 PM to 1:00 PM.

Volition's Mission and Innovations

VolitionRx is dedicated to advancing the science of epigenetics with the ultimate goal of saving lives and improving health outcomes for both people and animals. The Nu.Q® Vet Cancer Test is a testament to this mission, designed to facilitate earlier detection of cancers in dogs, thereby enhancing their quality of life and prolonging their lives through timely interventions. This innovative blood test is a vital tool for veterinarians, offering an essential ally in the fight against pet cancer.

The company's research and development efforts are based in Belgium, with additional innovation hubs located in the U.S. and London. Volition is focused on delivering tests that are not only effective but also accessible to a wider range of veterinary practices.

Conclusion

The upcoming WVC is not only a platform for Volition to showcase its innovations but also an opportunity for the veterinary community to engage with new technologies that can significantly alter the landscape of animal healthcare. The Nu.Q® Vet Cancer Test represents a pioneering step toward a future where early cancer detection is a norm rather than an exception in veterinary practices. With the presence of influential figures like Dr. Sue Ettinger and Dr. Brett Cordes, alongside engaging discussions at their booth, VolitionRx is poised to make a remarkable impact at this year's conference. This participation underscores Volition's role as a key player in veterinary diagnostics, and their continued efforts to improve the lives of pets facing cancer challenges.